scholarly journals Acute Effects of Graduated Elastic Compression Stockings in Patients with Symptomatic Varicose Veins: A Randomised Double Blind Placebo Controlled Trial

2018 ◽  
Vol 67 (2) ◽  
pp. 679 ◽  
Author(s):  
Stavros K. Kakkos ◽  
Marios Timpilis ◽  
Panayiotis Patrinos ◽  
Konstantinos M. Nikolakopoulos ◽  
Chrysanthi P. Papageorgopoulou ◽  
...  
2018 ◽  
Vol 55 (1) ◽  
pp. 118-125 ◽  
Author(s):  
Stavros K. Kakkos ◽  
Marios Timpilis ◽  
Panayiotis Patrinos ◽  
Konstantinos M. Nikolakopoulos ◽  
Chrysanthi P. Papageorgopoulou ◽  
...  

Thrombosis ◽  
2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Abir O. Kanaan ◽  
Jayne E. Lepage ◽  
Shabdis Djazayeri ◽  
Jennifer L. Donovan

Background. Postthrombotic syndrome (PTS) is a burdensome and costly complication of deep vein thrombosis (DVT). Up to 50% of patients with DVT will develop the disease within two years following the diagnosis of acute DVT. Various risk factors for developing PTS have been identified and different modalities have been used to prevent its development. Compression stockings have been studied for the prevention of PTS in patients diagnosed with proximal DVT. Methods. MEDLINE and EMBASE databases were searched to identify relevant original articles. Results. Several trials including two metaanalyses have examined the role of compression stockings for the prevention of PTS. Although most trials showed significant reduction in the development of PTS with the use of compression stockings, limitations in study design prevent the generalizability of the data. Two studies supported an individualized tailored duration especially in patients at low risk for developing the syndrome. A randomized double-blind placebo-controlled trial involving 800 patients is currently ongoing and may confirm the results of older studies. Conclusions. Clinical trials support the use of compression stockings in patients diagnosed with proximal DVT for the prevention of PTS.


1993 ◽  
Vol 8 (2) ◽  
pp. 77-81 ◽  
Author(s):  
S. E. Kranendonk ◽  
A. M. Koster

Objective: To study the efficacy and tolerability of O-(β-hydroxyethyl)-rutosides (HR) and compression stockings in the treatment of leg oedema and symptoms after varicose vein surgery. Design: A prospective double-blind, randomized, Parallel, placebo-controlled trial. Setting: Surgical department of a regional hospital. Patients: Forty patients undergoing venous surgery for varices associated with superficial insufficiency. Interventions: Saphenofemoral ligation, stripping of the entire long saphenous vein and removal of varicosities via 0.5 cm incisions. HR was given at 2 g/day (or Placebo) for 6 weeks starting on the first postoperative day. Twenty patients were randomized to each group. Main outcome measures: Leg volumes were measured by an automatic electronic-optic volumeter, prior to operation and again after 6 weeks and 3 months. Leg symptoms were recorded on days 1 and 10, weeks 3 and 6, and at 3 months. Results: There was no difference in leg volume between the two groups during the first 6 weeks when stockings Were worn, but the increase in oedema of the distal leg in the subsequent 6 weeks was significantly less in the HR group. Symptoms disappeared rapidly 3 weeks Postoperatively in both groups. Conclusions: Stockings are effective in controlling postoperative leg oedema and symptoms. The addition of HR can prevent subsequent oedema after removal of the stockings.


1997 ◽  
Vol 12 (1) ◽  
pp. 17-20 ◽  
Author(s):  
M. Vayssairat ◽  

Objective: To evaluate the effectiveness and best time course of prescription of 30 mg/day oral naftazone (N) in women with primary uncomplicated symptomatic varicose veins (PUSVV). Design: Double-blind, placebo (P)-controlled study. Setting: Multicentre study, coordinated by a University hospital in Paris, France. Patients: 270 women with PUSVV. Interventions: Treatment with naftazone (three dosage regimens) or placebo for 14 days. Main outcome measures: Comparison by ANOVA, at day 0 and after 14 days of treatment, of (1) clinical disability, using an analogue scale 100 mm long and (2) morning and evening leg volumes. Results: The reduction in disability at day 14 was 32 ± 23 mm in the N group versus 24 ± 20 in the P group, F = 6.35, p = 0.01. Best clinical efficacy was obtained in the subgroup given 30 mg N once a day at midday (35 ± 22 mm). Differences between morning leg volumes on days 0 and 14 were 19.3 ± 74 ml in the N group versus 5.5 ± 50 in the P group, p = 0.059. Conclusion: Naftazone was more effective than placebo for the clinical improvement of women with PUSVV.


1997 ◽  
Vol 27 (8) ◽  
pp. 860-867 ◽  
Author(s):  
V.A. VARNEY ◽  
J. EDWARDS ◽  
K. TABBAH ◽  
H. BREWSTER ◽  
G. MAVROLEON ◽  
...  

2001 ◽  
Vol 120 (5) ◽  
pp. A384-A384
Author(s):  
L MOLLISON ◽  
L TOTTEN ◽  
C HOVELL ◽  
K THAYNE ◽  
C CONNELLY ◽  
...  

2007 ◽  
Vol 177 (4S) ◽  
pp. 14-15
Author(s):  
Brian J. DeCastro ◽  
Jack R. Walter ◽  
Leah P. McMann ◽  
Andrew C. Peterson

Sign in / Sign up

Export Citation Format

Share Document